The license, which was granted following months of strict safety testing and evaluation by the Medicines and Healthcare Products Regulatory Authority (MHRA), allows the Centre to manufacture PET (Positron Emission Tomography) tracers in its high-tech sterile facilities and administer them to human participants in clinical trials. The license is one of only a handful issued in the UK.
PET scanning produces high-resolution images of internal organs and biological processes at work by injecting trace amounts of a radioactive compound, or ‘radiotracer’, into the part of the body to be scanned. Radioactive emissions from this tracer are then recorded by detectors within the scanner, and the resulting data processed by sophisticated software to create the images.
The trace levels of radioactivity are closely monitored for the safety of the patient, and diminish after a short time.
The license means the Centre can now develop, manufacture and use more complex radiotracers, such as those derived from the element Carbon-11 (11C). These will allow researchers to measure a wide range of complex molecular events such as cancer tumour growth, cell death, psychoses and chronic pain, as well as the effect of drugs designed to treat these conditions.
Such PET studies using advance tracers look set to inspire breakthroughs in research and improve the treatment of patients. The first to be enabled will investigate a possible link between inflammation in the central nervous system (CNS) and increased risk of stroke.
Lead researcher Dr Pippa Tyrrell of the University’s School of Medicine said: “This license means we can now measure CNS inflammation in subjects we know have an increased risk of stroke*, using one of the new tracers to detect activated immune cells in their brains. Around 125,000 people are affected by stroke each year in the UK and this approach could uncover vital new evidence on the role of inflammation; helping us to understand the risk factors and potentially modulate them.”
Ian Young, Quality Manager for the Centre, said “The MHRA’s requirements are very exacting and creating the extensive quality management system which has allowed us to progress to this level has involved a huge effort from all staff.”
Its Director Professor Karl Herholz said: “The award of this license is a key strategic milestone for the Centre, as we can now progress with the molecular imaging projects it is uniquely equipped to carry out. This approach to better-understanding the mechanisms of both the brain and cancer tumours is relatively under-explored, and we are very excited about its potential to inspire breakthroughs and improve patient treatments.”
Jon Keighren | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News